Titan Pharmaceuticals (TTNP) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Titan Pharmaceuticals in July 2026.
Titan Pharmaceuticals, Inc. is a pharmaceutical company. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus, and Nalmefene Implant, which is for the prevention of relapse in OUD patients following detoxification from opioids Its product development programs are in non-clinical stages of development.
Stock Performance Snapshot
Financial Health
Titan Pharmaceuticals is showing strong cash flow and book value, indicating solid financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring TTNP
Injectable Drug Revolution: What's Next Beyond Pills?
The UK's approval of GSK's long-acting HIV drug marks a pivotal shift from daily pills to less frequent injections. This theme focuses on the pharmaceutical innovators leading the charge in developing and commercializing long-acting therapeutic technologies.
Published: 17 October 2025
Explore BasketBeyond Opioids: The Race For New Painkillers
Vertex Pharmaceuticals has halted the development of its non-opioid painkiller, creating uncertainty but also a potential opening for competitors. This theme focuses on other pharmaceutical companies that could capture market share as they advance their own non-opioid treatments.
Published: 5 August 2025
Explore BasketWhy invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.